Aurobindo Pharma Limited has announced a forthcoming meeting of its Board of Directors scheduled for Monday, April 6, 2026. The primary agenda item for this meeting is to evaluate and consider a proposal for the buyback of the company’s fully paid-up equity shares. Consequently, the trading window, which was already closed for designated persons since April 1, 2026, will remain restricted until 48 hours after the publication of audited financial results for the year ended March 31, 2026.
Notice of Board Meeting and Agenda
Aurobindo Pharma Limited officially informed the stock exchanges regarding a forthcoming meeting of the Board of Directors, scheduled to convene on Monday, April 6, 2026. The crucial purpose of this meeting, as per the notification, is to deliberate upon and consider, inter alia, a proposal for the buyback of fully paid-up equity shares of the Company.
The consideration of the buyback proposal will also necessitate addressing all matters necessary and incidental thereto, ensuring compliance with the relevant provisions of the Companies Act, 2013, and the SEBI (Buy-back of Securities) Regulations, 2018, as amended.
Trading Window Closure Details
Further referencing the earlier communication dated March 23, 2026, the company confirmed the continuation of the trading window closure for all designated persons, connected persons, and their immediate relatives.
This closure commenced on April 01, 2026, and will persist until forty-eight hours after the declaration of the audited financial results for the financial year ending on March 31, 2026. The announcement explicitly states that the trading window shall be deemed closed in respect of the aforementioned buyback proposal as well.
Source: BSE
